Overview

Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy of Cipros 20 association in the treatment of dyslipidemia treatment.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
EMS
Treatments:
Ciprofloxacin
Rosuvastatin Calcium
Criteria
Inclusion Criteria:

- Participants of both sexes, aged 18 years or more;

- Participants with the diagnosed of dyslipidemia and with high or very high
cardiovascular risk, according to the Brazillian Guidelines on Dyslipidemia and
Prevention of Atherosclerosis;

- Signed consent.

Exclusion Criteria:

- Using medications that may interfere with the metabolism or serum levels of
triglycerides;

- Any clinical and laboratory findings that, in the judgment of the investigator, may
interfere with the safety of research participants;

- Presence of concomitant cardiovascular disease, renal failure and hepatic failure;

- Decompensated diabetes;

- Current smoking;

- History hypersensitivity to the active ingredients used in the study;

- Pregnancy or risk of pregnancy and lactating patients;

- History of alcohol abuse or illicit drug use;

- Participation in clinical trial in the year prior to this study.